SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is trending as investors react to the CMS finalizing a Medicare Advantage rate increase for 2027 that arrived higher than previous projections. The community remains divided between those viewing the news as a bullish recovery catalyst that creates a short squeeze, and others who remain skeptical of the long-term regulatory headwinds and ongoing sector volatility.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is trending as investors react to its strategic supply chain partnerships and the official disclosure of major hyperscaler collaborations that reinforce its critical role in AI infrastructure. The community is actively debating the stock's resilience amid broader semiconductor volatility, with many analyzing the disconnect between its strong fundamental outlook and recent price pressure.

Humana Inc. engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts. The CenterWell segment represents payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and home services. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

Humana Inc.

Humana Inc

Humana is seeing intense volatility and scrutiny as investors weigh its Medicare Advantage exposure against proposed regulatory changes and looming quarterly earnings. The community is sharply divided, with some traders actively betting on a potential bounce or M&A activity, while others are cautioning against the stock's multi-year lows and ongoing policy-driven headwinds.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

The community is heavily focused on Wendy's as a potential buyout candidate and a high-yield dividend play, with significant discussion surrounding unusual short interest and expectations for a major leadership announcement. Traders are actively debating whether the stock's current valuation represents a deep-value opportunity or a long-term trap, while many look toward potential M&A activity and international expansion to serve as catalysts for a rally.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is currently in the spotlight as investors track its potential for a bullish re-rating, driven by the successful closing of large asset-backed security transactions and active onboarding of new banking partners. While the stock has faced intense selling pressure tied to broader fintech sector volatility and geopolitical instability, the community remains divided between those betting on an explosive recovery fueled by solid GAAP profitability and others warning of risks from macro-economic shifts.

Enovix Corp. engages in the design and development of silicon-anode lithium-ion batteries. The firm's proprietary 3D cell architecture increases energy density and maintains a high cycle life. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable utilization of renewable energy. The company was founded by Mr. Harrold Jones Rust, III, Ashok Lahiri, and Murali Ramasubramanian in November 2006 and is headquartered in Fremont, CA.

Enovix Corporation

Enovix Corp

Enovix is currently experiencing significant market volatility and testing support levels as investors weigh persistent manufacturing challenges at the Malaysia facility against the company's long-term potential in high-energy-density battery technology. The community is actively debating the company's path to commercial scale, with many focused on upcoming milestones related to customer qualification programs and management's ability to navigate production bottlenecks.

Centene Corp. is a healthcare enterprise, which engages in the provision of programs and services to government sponsored healthcare programs. It operates through the following segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment includes the Temporary Assistance for Needy Families program, Medicaid Expansion programs, the Aged, Blind or Disabled program, the Children's Health Insurance Program, Long-Term Services and Supports, Foster Care, Medicare-Medicaid Plans, which cover beneficiaries who are dually eligible for Medicaid and Medicare, and other state-based programs. The Medicare segment consists of Medicare Advantage, Medicare Supplement, Dual Eligible Special Needs Plans, and Medicare Prescription Drug Plans. The Commercial segment is involved in the Health Insurance Marketplace product along with individual, small group, and large group commercial health insurance products. The Other segment refers to pharmacy operations, Envolve Benefit Options’ vision and dental services, clinical healthcare, behavioral health, the TRICARE program, and corporate management companies. The company was founded in 1984 and is headquartered in St. Louis, MO.

Centene Corp.

Centene Corp. (CNC) is trending as investors react to ongoing uncertainty surrounding the future of Affordable Care Act (ACA) subsidy extensions. The community is actively debating the potential impact of proposed policy changes, with many monitoring for signs of institutional accumulation and long-term value despite broader sector volatility and legislative headwinds.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

Aehr Test Systems is currently seeing high volatility and intense community discussion following news of new production orders for its Sonoma systems, which investors view as validation of its critical role in the scaling of AI infrastructure. While bulls are closely monitoring for further contract announcements and hyperscaler adoption, skeptics remain cautious due to the stock's cyclical history and the need for sustained revenue growth beyond initial evaluations.

Oscar Health, Inc. is a healthcare insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is capturing significant investor attention ahead of its quarterly results, with the community actively debating whether the stock's recent price compression is a long-term entry point or a reflection of underlying operational risks. While some retail traders are betting on a recovery fueled by strong membership growth and management's focus on AI-driven efficiency, others remain skeptical, pointing to recurring earnings misses and volatility in the health insurance sector.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is generating significant community buzz as participants debate its longevity, with many highlighting its history dating back to 2011 as evidence that it transcends typical short-term market trends. Supporters are actively positioning it as a cultural phenomenon and a long-term play, frequently drawing comparisons to major established assets while navigating discussions around its official contract address.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026

Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026 Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026 PR Newswire CAMBRIDGE, Mass. and HOUSTON, April 6, 2026 Live video webcast...

Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement PR Newswire CAMBRIDGE, Mass. and HOUSTON, April 2, 2026 CAMBRIDGE, Mass. and HOUSTON, April 2, 2026 /PRNewswire/ --Decoy Therapeutics, Inc...

Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform

Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform Decoy Therapeutics Enters Strategic...

Decoy Therapeutics Announces 1-for-12 Reverse Stock Split

Decoy Therapeutics Announces 1-for-12 Reverse Stock Split Decoy Therapeutics Announces 1-for-12 Reverse Stock Split PR Newswire CAMBRIDGE, Mass., March 5, 2026 CAMBRIDGE, Mass., March 5, 2026...

Decoy Therapeutics Joins Webull Corporate Connect Service Platform

Decoy Therapeutics Joins Webull Corporate Connect Service Platform Decoy Therapeutics Joins Webull Corporate Connect Service Platform PR Newswire CAMBRIDGE, Mass. and HOUSTON, Feb. 11, 2026 - Connect...

Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial Decoy Therapeutics to Participate in the Corporate Connect Webinar Series...

Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform

Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform Decoy Therapeutics Reaches Global...

Decoy Therapeutics, Inc. operates as a preclinical-stage biotechnology company. It engages in leveraging machine learning and AI tools alongside high-speed synthesis techniques to rapidly design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs. The company was founded by Frederick E. Pierce, Barbara Hibner, Peter Marschel, Michael Lipp, and Jodi Cooper in 2020 and is headquartered in Houston, TX.

DCOY
Decoy Therapeutics Inc.

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest DCOY News

DCOYDecoy Therapeutics Inc.